Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Lemonade Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.57 (market cap $6.04B), while Lemonade Inc trades at $46.67 (market cap $3.63B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Lemonade Inc for 27 Days on average.
| IOVA | LMND | |
|---|---|---|
Market Cap | $6.04B | $3.63B |
Volume | 14,805,993 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $14.82 | $96.57 |
52-Week Low | $1.81 | $43.91 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $5.97B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lemonade (LMND) trades at $46.83, up 1.14% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth is accelerating, reaching $738M in 2025, with a narrowing net loss margin from -116% in 2022 to -22.4% in 2025. The company is expanding geographically and product-wise, supported by AI-driven efficiency, targeting EBITDA profitability by late 2026.
The outlook is mixed: strong growth and path to profitability present opportunity, but persistent losses, high valuation multiples, and bearish technicals pose risks. The consensus price target of $67 implies significant upside if execution continues, but investor sentiment remains divided given the stock's high volatility and unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
